Chiasma (NASDAQ: CHMA) and Catalyst Biosciences (NASDAQ:CBIO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, dividends, profitability and risk.

Valuation and Earnings

This table compares Chiasma and Catalyst Biosciences’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Chiasma $10,000.00 4,388.40 -$61.11 million ($1.17) -1.54
Catalyst Biosciences $400,000.00 75.32 -$16.94 million ($13.12) -0.53

Catalyst Biosciences has higher revenue and earnings than Chiasma. Chiasma is trading at a lower price-to-earnings ratio than Catalyst Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Chiasma and Catalyst Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Chiasma N/A -36.49% -32.48%
Catalyst Biosciences -2,438.50% -91.67% -55.28%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Chiasma and Catalyst Biosciences, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Chiasma 1 0 0 0 1.00
Catalyst Biosciences 0 0 2 0 3.00

Catalyst Biosciences has a consensus price target of $10.50, indicating a potential upside of 50.21%. Given Catalyst Biosciences’ stronger consensus rating and higher probable upside, analysts clearly believe Catalyst Biosciences is more favorable than Chiasma.

Insider & Institutional Ownership

54.6% of Chiasma shares are held by institutional investors. Comparatively, 31.5% of Catalyst Biosciences shares are held by institutional investors. 3.8% of Chiasma shares are held by company insiders. Comparatively, 5.0% of Catalyst Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk & Volatility

Chiasma has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500. Comparatively, Catalyst Biosciences has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500.

Summary

Catalyst Biosciences beats Chiasma on 7 of the 13 factors compared between the two stocks.

Chiasma Company Profile

Chiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The Company is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The Company’s TPE technology enhances the absorption through the intestinal wall of drugs. The Company also focuses on developing CH2 for Orphan indication.

Catalyst Biosciences Company Profile

Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company’s advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.

Receive News & Ratings for Chiasma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.